Polymer Nanoparticle-Mediated Delivery of Oxidized Tumor Lysate-Based Cancer Vaccines.

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: author
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_561527E3BDD3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Polymer Nanoparticle-Mediated Delivery of Oxidized Tumor Lysate-Based Cancer Vaccines.
Journal
Macromolecular bioscience
Author(s)
Berti C., Graciotti M., Boarino A., Yakkala C., Kandalaft L.E., Klok H.A.
ISSN
1616-5195 (Electronic)
ISSN-L
1616-5187
Publication state
Published
Issued date
02/2022
Peer-reviewed
Oui
Volume
22
Number
2
Pages
e2100356
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Cancer vaccination is a powerful strategy to combat cancer. A very attractive approach to prime the immune system against cancer cells involves the use of tumor lysate as antigen source. The immunogenicity of tumor lysate can be further enhanced by treatment with hypochlorous acid. This study explores poly(lactic-co-glycolic acid) (PLGA) nanoparticles to enhance the delivery of oxidized tumor lysate to dendritic cells. Using human donor-derived dendritic cells, it is found that the use of PLGA nanoparticles enhances antigen uptake and dendritic cell maturation, as compared to the use of the free tumor lysate. The ability of the activated dendritic cells to stimulate autologous peripheral blood mononuclear cells (PBMCs) is assessed in vitro by coculturing PBMCs with A375 melanoma cells. Live cell imaging analysis of this experiment highlights the potential of nanoparticle-mediated dendritic-cell-based vaccination approaches. Finally, the efficacy of the PLGA nanoparticle formulation is evaluated in vivo in a therapeutic vaccination study using B16F10 tumor-bearing C57BL/6J mice. Animals that are challenged with the polymer nanoparticle-based oxidized tumor lysate formulation survive for up to 50 days, in contrast to a maximum of 41 days for the group that receives the corresponding free oxidized tumor lysate-based vaccine.
Keywords
cancer vaccines, human donor-derived dendritic cells, in vitro real time live cell imaging analysis, nanoparticles, oxidized tumor lysate, in vitro real-time live cell imaging analysis
Pubmed
Web of science
Open Access
Yes
Create date
03/12/2021 11:12
Last modification date
19/07/2023 5:55
Usage data